Course and treatment of diabetes mellitus in the context of COVID-19
https://doi.org/10.14341/DM12418
Abstract
In 2020, the world is facing a historically unparalleled public health challenge associated with the invasion of the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This is also a challenge for the healthcare systems worldwide. Patients with diabetes mellitus (DM) are most vulnerable to COVID-19 because of the peculiarities of their immune response to a virus attack and due to their high susceptibility to viral activity because of hyperglycemia and other comorbid conditions and obesity that often accompany DM. The severity of the COVID-19 disease requires a mandatory review of the usual anti-hyperglycemic therapy. Maintaining optimal glycemic control and preventing the development of ketoacidosis remain extremely important; therefore, insulin becomes the priority drug for glycemic control in most cases. The search for new drugs to fight against the coronavirus infection continues with new randomised clinical drug trials being launched. Innovative anti-diabetic agents are also being tested as candidates for potentially effective anti-coronavirus agents.
About the Authors
Marina V. Shestakova
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD, Professor
Natalya G. Mokrysheva
Endocrinology research centre
Russian Federation
Russian Federation
MD, PhD, Professor
Ivan I. Dedov
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD, Professor
References
1. World Health Organization. Coronavirus disease (COVID-2019) situation reports. Avalable from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
2. Epidemiology Working Group for Ncip Epidemic Response. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. (In Chinese)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145−151. doi: https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003
3. CDC. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 − United States, February 12 − March 28, 2020. MMWR. 2020;69(13):382–386.
4. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. doi: https://doi.org/10.1001/jama.2020.4683
5. International Diabetes Federation. IDF Diabetes Atlas, 9th dn. Brussels, Belgium; 2019.
6. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–310. doi: https://doi.org/10.1016/j.dsx.2020.04.004
7. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395–403. doi: https://doi.org/10.1016/j.dsx.2020.04.018
8. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: https://doi.org/10.1016/j.cell.2020.02.052.
9. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi: https://doi.org/10.1038/s41368-020-0074-x
10. Zou X, Chen K, Zou J, et al. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection. Front Med. 2020. doi: https://doi.org/10.1007/s11684-020-0754-0
11. Rabi FA, Al Zoubi MS, Kasasbeh GA, et al. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231–235. doi: https://doi.org/10.3390/pathogens9030231
12. Roca-Ho H, Riera M, Palau V, et al. Characterization of ACE and ACE2 287 expression within different organs of the NOD mouse. Int J Mol Sci. 2017;18(3). pii: E563. doi: https://doi.org/10.3390/ijms18030563
13. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 epidemic. J Medical Virology. 2020. doi: https://doi.org/10.1002/jmv.25887
14. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727−732. doi: https://doi.org/10.1080/22221751.2020.1746199
15. Wang Q, Fang P, He R, et al. O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci Adv. 2020;6(16):eaaz7086. doi: https://doi.org/10.1126/sciadv.aaz7086
16. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;e3319. doi: https://doi.org/10.1002/dmrr.3319
17. Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623−628. doi: https://doi.org/10.1111/j.1464-5491.2006.01861.x
18. Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;1932296820924469. doi: https://doi.org/10.1177/1932296820924469
19. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049−6057. doi: https://doi.org/10.18632/aging.103000
20. Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280−284. doi: https://doi.org/10.1136/pmj.2005.039032
21. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 − COVID-NET, 14 states, march 1–30, 2020. MMWR Morb Mortal WklyRep. 2020;69(15):458–464. doi: https://doi.org/http://dx.doi.org/10.15585/mmwr.mm6915e3
22. Hales СМ, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief No. 360, February 2020. Avalable from: https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf
23. Simmonet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020. Avalable from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.22831
24. Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19), 6-я версия от 28.04.20 (static-1.rosminzdrav.ru). — Минздрав России, 2020. [Vremennyye metodicheskiye rekomendatsii: profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19), 6-ya versiya ot 28.04.20 (static-1.rosminzdrav.ru). Minzdrav Rossii; 2020. (In Russ.)] Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_%D0%9CR_COVID-19_v6.pdf. Ссылка активна на 28.04.2020.
25. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020. pii: S2213-8587(20)30152-2. doi: https://doi.org/10.1016/S2213-8587(20)30152-2
26. Egi M. Acute glycemic control in diabetics. How sweet is optimal? Con: Just as sweet as in nondiabetic is better. J Intensive Care. 2018;6:70. doi: https://doi.org/10.1186/s40560-018-0337-1
27. Mendy A, Gopal R, Alcorn JF, Forno E. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology. 2019;24(7):646−651. doi: https://doi.org/10.1111/resp.13486
28. Ho T, Huang C, Tsai Y, et al. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res. 2019;20(1):69. doi: https://doi.org/10.1186/s12931-019-1035-9
29. Мокрышева Н.Г., Галстян Г.Р., Киржаков М.А., и др. Рекомендации для врачей по лечению эндокринных заболеваний в условиях пандемии COVID-19. Пандемия COVID-19 и эндокринопатии. — М.: ФГБУ «НМИЦ эндокринологии», 2020. [Mokrysheva NG, Galstyan GR, Kirzhakov MA, et al. Rekomendatsii dlya vrachey po lecheniyu endokrinnykh zabolevaniy v usloviyakh pandemii COVID-19. Pandemiya COVID-19 i endokrinopatii. Moscow: FGBU «NMITS endokrinologii»; 2020. (In Russ.)] Доступно по: https://www.endocrincentr.ru/rekomendacii-dlya-vrachey-po-lecheniyu-endokrinnyh-zabolevaniy-v-usloviyah. Ссылка активна на 28.04.2020.
30. Гринева Е.Н., Халимов Ю.Ш., Бабенко А.Ю., и др. Рекомендации по ведению больных COVID-19 и эндокринными заболеваниями в период пандемии. — М.: ФГБУ «НМИЦ им. В.А. Алмазова», 2020. [Grineva EN, KHalimov YuSh, Babenko AYu, et al. Rekomendatsii po vedeniyu bol’nykh COVID-19 i endokrinnymi zabolevaniyami v period pandemii. Moscow: FGBU «NMITS im. V.A. Almazova»; 2020. (In Russ.)] Доступно по: http://www.almazovcentre.ru/?p=62944. Ссылка активна на 28.04.2020.
31. Royal Australian College of General Practitioners (RACGP). Diabetes management during the coronavirus pandemic: be proactive and prepared. Avalable from: https://www.racgp.org.au/getmedia/97a5abb4-1290-42cb-91c0-eabcaa8ca590/Diabetes-management-during-coronavirus-pandemic_1.pdf.aspx
32. Hartmann-Boyce J, Morris E, Goyder C, et al. Managing diabetes during the COVID-19 pandemic. [cited 8 April 2020] Avalable from: https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/
33. Christiansen C, Johansen M, Christensen S, et al. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit Care. 2013;17(5):R192. doi: https://doi.org/10.1186/cc12886
34. Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19). [cited 17 April 2020] Avalable from: https://clinicaltrials.gov/ct2/show/NCT04350593
35. Wiviott SD, Raz I, Bonaca MP, et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347−357. doi: https://doi.org/10.1056/NEJMoa1812389
36. McMurray JJ, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995−2008. doi: https://doi.org/10.1056/NEJMoa1911303
37. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып. // Сахарный диабет. — 2019. — Т. 22. — №S1-1. — C. 1–144. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(S1-1):1–144. (In Russ.)] doi: https://doi.org/10.14341/DM221S1
38. Petrillo MG, Bortner C, Cidlowski JA. Glucocorticoids: inflammation and immunity. The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease.2017;43−63. doi: https://doi.org/10.1007/978-3-319-45950-9_3
39. Russell B, Moss C, Rigg A, Hemelrijck MV. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancer. 2020;14:1023. doi: https://doi.org/10.3332/ecancer.2020.1023
40. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52(Pt 8):715–720. https://doi.org/10.1099/jmm.0.05320-0
41. Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. (In Chinese)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E004. https://doi.org/10.3760/cma.j.cn112148-20200220-00105
42. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. [cited 13 March 2020] Avalable from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
43. Аmerican Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. [cited 20 March 2020] Avalable from: https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp
Supplementary files
|
|
1. Fig. 1. Localization of expression of angiotensin-converting enzyme type 2 in human tissues (adapted [9]): ACE2 - Angiotensin-converting enzyme 2. | |
| Subject | ||
| Type | Other | |
View
(154KB)
|
Indexing metadata ▾ | |
|
|
2. Fig. 2. Classification of COVID-19 by severity [24]. | |
| Subject | ||
| Type | Other | |
View
(378KB)
|
Indexing metadata ▾ | |
Review
For citations:
Shestakova M.V., Mokrysheva N.G., Dedov I.I. Course and treatment of diabetes mellitus in the context of COVID-19. Diabetes mellitus. 2020;23(2):132-139. (In Russ.) https://doi.org/10.14341/DM12418
Views:
35515
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
